Drugs

Why government must unlock biotech’s potential to maximise Longevity

Breanna Deutsch joins us for a guest editorial to advocate for the increased prioritisation of government funding for Longevity in the US. Breanna Deutsch has...

ChromaDex releases results for NR study in C19 patients

Phase 2 study finds addition of a nutritional protocol into Covid-19 care pathway reduces recovery time to 6.6 days from 9.3 in mild-to-moderate patients. ChromaDex...

Using small data to target Alzheimer’s

NetraMark CEO on using AI to identify novel targets for treatment of Alzheimer’s disease. Despite the billions spent on research and development into treatments for...

The Faloon regimen: we connect with a RAADfest icon

Bill Faloon is pushing Longevity forward to "enable biological senescence to go in reverse". Totally RAADfest: Ahead of this week's Revolution Against Aging and Death...

Combining existing medicines to target aging

Rejuvenate Biomed closes in on €9 million funding round for human trials of sarcopenia-targeted combined drug. Already well-known for its beer and bureaucracy to its...

Longevity marketing and the need for clarity

Dr Oliver Zolman makes the case for Longevity companies adopting a checklist when it comes to making anti-aging claims. When it comes to marketing in...

Insilico opens Pandomics box for AI target discovery

Insilico announces Pandomics, an AI-powered hypothesis generation engine that interprets OMICS and text-based data for the discovery and analysis of new therapeutic targets. Insilico is...

Reproductive Longevity – taking the geroscience approach

Applying geroscience interventions to fertility pathways can promote reproductive Longevity. Dr Joon Yun is President and Managing Partner of Palo Alto Investors, LP, a hedge...

Inflammaging biotech acquired by Roche for €380m

One of the largest deals in Irish biotech history sees Roche gain rights to full Inflazome portfolio. The Swiss company Roche has bought Dublin-based biotech...

Psychobiome: trusting your gut for Longevity

Scientists studying how the microbiome affects our mood aim to develop gut microbiome-modulating formulations to treat depression and other brain diseases. Recent work from Katya...

Longevity-extending compounds key to neurodegenerative treatment

Compounds found to increase lifespan in animal models could hold the key to treatments for debilitating neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.  Neurodegenerative...

New immune aging drug brings Longevity and C19 hope

Phase 2-ready drug can treat and reverse immune aging, BioAge claims. BioAge Labs' in-licensed clinical-stage therapy has potential for treating immune aging in older patients...

Epigenetic reprogramming: the road to reversing time

Epigenetic modifications – also known as “aging clocks” – have emerged as promising markers of aging and accurate predictors of age-related diseases; they're a hot...

Longevity trials: time to change the approach?

Leading academic says high profile trial failures should drive changes in how we approach trials for drugs that target aging. Following the recent clinical trial...

Insilico teams-up with Intel to identify disease progression risk

Insilico's new COVIDomic platform combines cutting-edge AI with Intel Xeon processors and could turn the pandemic tide. Insilico have been rather busy lately; a couple...

The metformin debate swings both ways

Research on metformin is not at the beginning of the end, but it is, perhaps, at the end of the beginning. The drug giveth and...

Leading academic sees “great promise” in longevity supplements

Buck professor Brian Kennedy talks about AKG and the potential for supplements to deliver real anti-aging benefits. Following Tuesday’s news from the Buck Institute about...

ARDD 2020: Exclusive interview with Calico’s PI

Calico's Adam Freund tells us about using a network approach to aging – and that PAPP-A does preach. It's ARDD week; the annual Aging Research &...

AKG study first to show “dramatically compressed” morbidity in mammals

The Buck's new peer-reviewed study of alpha-ketoglutarate shows a significant reduction in frailty in older mice, resulting in compression of late-life morbidity. The Buck Institute...

Relation-Mila collaboration wins $1.3m Gates Foundation Award to fight COVID-19

Relation receives $1.3m grant funding from the Gates Foundation to identify COVID-19 therapeutic candidates. Relation Therapeutics (a Juvenescence-incubated company) and Mila, the Montreal-based AI research...

Latest articles

Peptide molecule causes cancer cells to self destruct

New breakthrough by a team led by eminent oncologist Loren Walensky brings new hope for future cancer treatments – and Longevity.  Everyone needs a way...

WHO portal brings aging data together

We live in a world driven by data and the World Health Organization (WHO) has now launched the first data portal to bring together...

The natural medicine war chest to fight aging

Quicksilver's liposomal delivery system boasts a non-invasion of the body patchers. Colorado-based Quicksilver Scientific manufactures a range of supplements from immunity boosters to NAD+. By...

Jim Mellon and Phil Newman: Longevity interviews

Master Investor is a publication that helps private investors to take charge of their financial destiny: covering a range of subjects, from shares to...